ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer
Washington, D.C., June 9, 2014 – A research study led by cancer specialists at MedStar Washington Hospital Center found that African-American women frequently present with biologically less favorable subtypes of breast cancer. Researchers at the Read More
Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New research involving Agendia’s genomic tests MammaPrint®, BluePrint®, TargetPrint® and TheraPrint®, as well as its ColoPrint® Colon Cancer Genomic Profile, will be reported at the 2014 Read More
Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports
Presentations to American Society of Breast Surgeons Detail Clinical Insights from MammaPrint and BluePrint Genomic Tests IRVINE, CA and AMSTERDAM, May, 7 2014 – New evidence showing that the MammaPrint® and BluePrint® tests provide insights Read More
Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development
Companies Will Apply Agendia Oncology Biomarker Expertise to Daiichi Sankyo Pharmaceutical Research IRVINE, CA and AMSTERDAM, April 24, 2014 – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized Read More